We wish to inform you that at the meeting of the Board of Directors of the Corporation held today i.e., May 7, 2021, the Board approved the audited financial results of the Corporation (both standalone and consolidated) for the year ended March 31, 2021, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations). We would like to state that the statutory auditors of the Corporation have issued audit reports with unmodified opinion on the financial statements. A copy of the said results along with the Reports issued by the Statutory Auditors of the Corporation with unmodified opinion are enclosed herewith as Annexure A. The same are being uploaded on the website of the Corporation i.e.
DGAP-News: APONTIS PHARMA AG / Key word(s): IPO
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
06.05.2021 / 20:09
The issuer is solely responsible for the content of this announcement.
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
Total placement volume of EUR 101 million including over-allotment and upsize options
Mark Fedosiewich Acquires Shares of Vior Inc.
Acquiror ), President, Chief Executive Officer and a director of Vior Inc. (the
Corporation ), announces that he has directly acquired on May 5, 2021, 92,000 common shares of the Corporation in the secondary market. Out of the 92,000 common shares, 77,000 common shares were acquired at a price of $0.19 per share and 15,000 common shares were acquired at a price of $0.195 per shares (the
Transaction ).
Immediately prior to the closing of the Transaction, the Acquiror held, directly or indirectly, (i) 7,182,000 common shares of the Corporation, representing 9.997% of the issued and outstanding common shares, (ii) warrants entitling the Acquiror to purchase up to 1,751,000 common shares of the Corporation and (iii) options entitling the Acquiror to purchase up to 1,180,000 common shares of the Corporation. Assuming the exercise of all warrants and options held by the Acquiror, prior to the closing of the Transaction, the Acquiror wou
Share:
VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE)
Novo Resources Corp. (
Novo or the
Company ) (TSX:NVO, NVO.WT, OTCQX:NSRPF) is pleased to report that it has closed its previously announced brokered private placement (the
Offering ) of special warrants of the Company (
Special Warrants ) to raise gross proceeds of approximately C$26.4 million. A syndicate of agents led by Clarus Securities Inc. and Stifel GMP as co-lead agents, together with PI Financial Corp., Haywood Securities Inc., CIBC World Markets Inc., and Echelon Wealth Partners Inc. (collectively, the
Agents ), exercised their over-allotment option to increase the size of the Offering from C$22 million to C$26.4 million.
JMC Projects (India) Ltd board to consider FY21 results on May 10, 2021 equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.